Synthonics Receives License to Conduct Industrial Hemp Research

May 30, 2017

Synthonics, Inc. announced receipt of a license from the Commonwealth of Virginia's Department of Agriculture and Consumer Services (VDACS) to possess industrial hemp, which will allow Synthonics to research industrial hemp in their laboratory in Blacksburg, VA. This research will be conducted as a component of a VDACS-approved industrial hemp research program managed by a Virginia public institution of higher education.

Dr. Tom Piccariello, President and Chief Science Officer of Synthonics, stated: "We are very pleased that VDACS has granted us a license that will enable us to conduct research with industrial hemp. Industrial hemp could become a staple crop for the state of Virginia for many products. Our focus will be in applying the proprietary extraction process we have developed for use with medical marijuana to industrial hemp. The environmentally friendly process produces a purer (95% or more cannabinoid content) and more consistent powder in less time and at less cost than traditional purification processes. We believe that a pure powder of Cannabidiolic Acid (CBDA) from hemp leaves could have significant medical value. Recent preclinical studies have shown the potential medicinal benefits of CBDA, especially as therapy for anticipatory nausea in cancer patients on chemotherapy. CBDA also has anti-inflammatory and analgesic activity."

Ken Slepicka, CEO of Synthonics stated "Our goal is not only to develop a purification process of the hemp plant, but also to apply our metal coordinated technology to the pure CBDA that is derived from the hemp plant to produce a metallo-CBDA compound that can be more readily absorbed into the bloodstream to provide a faster onset of action for people with nausea and chronic pain. We are very excited for this opportunity to help people with these conditions through this license."

Synthonics Completes Cannabis Purification Process and Plans the Development of Metal Coordinated Cannabis Compounds for FDA Approval

March 23, 2017

Synthonics announced today that they have completed the development of a cannabis purification process and plans the development of metal coordinated cannabis compounds for eventual FDA approval to treat anticipatory nausea, chronic pain, refractory seizures, and other neurological disorders.

"We are pleased to report that we have completed the development of a purification process that converts extracted cannabis resin, which on average contains only 65% cannabis, to over 98% pure cannabis powder using our scalable extraction process. We believe that this novel method will save cannabis cultivators at least 40% of the cost of goods sold and greatly streamline their production operations" said Ken Slepicka, CEO of Synthonics. "Additionally, this process will allow the production of medical infused products free of unwanted plant material and other potential contaminants. We are planning to partner with cannabis cultivators and/or marijuana infused product companies in the states that have legalized medical marijuana."

"This efficient and inexpensive process to produce pure cannabis compounds will further our development of cannabis-based pharmaceuticals and ultimately lead to seeking regulatory approval to treat anticipatory nausea and other medical conditions" said Dr. Tom Piccariello, President and Chief Science Officer of Synthonics. "We want to thank Cresco Labs in IL as well as Harvest Inc. in AZ, both medical cannabis companies, for their support during our purification process development" said Ken Slepicka.

Synthonics Awarded Patents in Europe, Canada and Australia

February 2, 2017

Synthonics announced today the allowance of European patent EPO 14105/13, Canadian patent 2627343 both titled Metal Coordinated Compositions (allowing a claim for a metallo-Triiodothyronine) and Australian patents 2013205471, Metal Coordinated Compositions (claims for 15 metallo-compounds), 2013205088 Frequency Modulated Drug Delivery (FMDD) and 2011326137 Bismuth Containing Compounds for Modulating Properties of Biologically Active Agents.

"We are encouraged that Europe, Canada and Australia along with the US are recoginizing the novelness of our metal coordination invention," said Synthonics CEO, Kenneth Slepicka. "To have global reach with our patents increases the value of our patent portfolio and reduces the risks for a potential licensor to commercialize one of our a metallo-compounds worldwide."

Synthonics Awarded Metal Coordinated Compositions Patents

January 30, 2017

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals (MCP), announced today the allowance of US patent applicatons 14/290.877 and 14/547,803. This allowance from the United States Patent Office (USPTO) increases Synthonic's composition of matter patents to over 50 metallo-drugs.

"These newly allowed patents continue to demonstrate the novelness of our metal coordinated technology and is proving to follow our patent strategy to continue to add additional metallo-drugs from the list of drugs from our original patent application " said Synthonics CEO, Kenneth Slepicka. "Intellectual property is important to our business and to our company and we are pleased that the USPTO recognizes our unique invention by allowing these additional metallo-drugs in a relatively short period of time."